Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linagliptin for liver fibrosis indices in non-diabetic NAFLD
IRCT20260513069383N1Phase 3Recruiting
- Sponsor
- Tabriz University of Medical Sciences
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in metabolic dysfunction-associated steatotic liver disease (MASLD) comparing Linagliptin with Placebo (2 arms). Primary endpoints: FIB-4, APRI and 1 more. Started Aug 2026; status: recruiting.
02
Drugs
linagliptin
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on IRCT20260513069383N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20260513069383N1.